IDIX has initiated a Phase II clinical trial evaluating IDX184+ SoC for 14 days and doses of up to 200mg (Patients will continue on treatment with pegylated interferon and ribavirin for 14 more days): <a href="http://finance.yahoo.com/news/Idenix-Pharmaceuticals-prnews-2318795928.html/print?x=0" rel="nofollow" target="_blank">http://finance.yahoo.com/news/Idenix-Pharmaceuticals-prnews-2318795928.html/print?x=0</a>